Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, is pleased to announce the presentation of the results of the Phase Ib study of THN201, “Effects of THN201, a combination of donepezil and low dose mefloquine, on cognition and quantitative EEG in healthy subjects during a scopolamine challenge,” by Professor Régis Bordet, principal investigator for the THN201 study (University of Lille, Lille Teaching Hospital, Inserm), at the CTAD virtual conference from 4 to 7 November at 1pm CET.
